TETRAULT LYNN A. 4

4 · RHYTHM PHARMACEUTICALS, INC. · Filed Jun 25, 2026

AI-generated summary of this filing

Updated Jun 25, 2026

RHYTHM (RYTM) Director Lynn A. Tetrault Exercises Options, Receives RSUs

What Happened

Lynn A. Tetrault, a director of Rhythm Pharmaceuticals (RYTM), recorded an exercise/conversion of 4,712 derivative securities on 2026-06-23 (Form 4 shows a matching disposition of 4,712 derivatives at $0). On 2026-06-24 she was granted two restricted stock unit (RSU) awards totaling 6,015 RSUs (3,691 + 2,324) at $0 per unit. The filing reports no cash proceeds or sale prices for the 6/23 disposition.

Key Details

Transaction dates: 2026-06-23 (exercise/conversion and reported disposition) and 2026-06-24 (RSU grants).
Reported prices/values: exercise/conversion listed with N/A and a reported disposition price of $0; RSU grants at $0 (typical for awards). No cash proceeds are shown.
Shares after transaction: the filing does not state total shares owned after these transactions.
Relevant footnotes from the filing:
- F1: Each RSU = contingent right to one share of common stock.
- F2/F4: Some RSUs are noted as fully vested and/or vest upon the earlier of June 24, 2027 or the day before the 2027 annual meeting (footnotes indicate different RSU vesting treatments in the filing).
- F3: Options referenced vest by the earlier of June 24, 2027 or the day before the 2027 annual meeting, subject to continued service.
Timeliness: Filing date 2026-06-25 for transactions dated 6/23–6/24/2026 — no late filing flagged in the report.

Context

The Form 4 records an exercise/conversion of derivative securities (transaction code M) and a corresponding disposition at $0; the filing does not show an open-market sale or cash proceeds, so this appears to be a conversion/transfer event rather than a market sale.
The 6,015 RSUs are awards (transaction code A) and represent contingent rights to receive shares; some RSUs in the filing are described as fully vested while others have future vesting conditions per footnotes.
Awards and exercises are routine insider events and are not, on their own, a clear buy/sell market signal — purchases (out-of-pocket buys) tend to carry more informational weight for investors.

Form 4

Period: 2026-06-23

Director

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-06-23+4,712→ 11,712 total
Exercise/Conversion
Restricted Stock Units
[F1][F2]
2026-06-23−4,712→ 0 total
→ Common Stock (4,712 underlying)
Award
Stock Option (right to buy)
[F3]
2026-06-24+3,691→ 3,691 total
Exercise: $107.55Exp: 2036-06-23→ Common Stock (3,691 underlying)
Award
Restricted Stock Units
[F1][F4]
2026-06-24+2,324→ 2,324 total
→ Common Stock (2,324 underlying)

Footnotes (4)

[F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
[F2]The restricted stock units are fully vested. The restricted stock units have no expiration date.
[F3]The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date.
[F4]The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

Signature

/s/ Stephen Vander Stoep, attorney-in-fact for Lynn A. Tetrault|2026-06-25

1 file